ASTS
AST SpaceMobile, Inc.
ASTS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
MDA
MDA Space Ltd
MDA has a slight edge over ASTS overall, supported by lower modeled downside.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Strong |
MDA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is weak.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
MDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 28x | $29.16 | — |
| Cheap | 49x | $27.91 | -4.3% |
| Fair | 51x | $28.95 | -0.7% |
| Current | 51x | $29.16 | — |
| Expensive | 57x | $32.29 | +11% |
Historical ranges are pointers, not guarantees.
MDA's PE is 51x, but its earnings don't support one, so it isn't a reliable read right now.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
MDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for MDA, but weaker profitability. However, they disagree widely on these estimates.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
MDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.06 | +85% |
| Q2 2026 | $0.57 | -14% |
| Q1 2026 | $0.59 | +3.5% |
| Q4 2025 | $0.61 | +30% |
| Q3 2025 | $0.61 | +49% |
| Q2 2025 | $0.66 | +128% |
| Q1 2025 | $0.57 | +104% |
| Q4 2024 | $0.47 | +57% |
| Q3 2024 | $0.41 | +52% |
MDA has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS's revenue has grown year over year for 11 quarters in a row: $42M last quarter, up 187% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
MDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $351M | +28% |
| Q1 2026 | $333.7M | +37% |
| Q4 2025 | $363.4M | +51% |
| Q3 2025 | $294.2M | +41% |
| Q2 2025 | $274.2M | +55% |
| Q1 2025 | $243.9M | +58% |
| Q4 2024 | $240.9M | +56% |
| Q3 2024 | $208.7M | +39% |
MDA's revenue has grown year over year every quarter since early 2022: $351M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 4.5% | -5.8 points |
| Q1 2026 | 7% | -3.1 points |
| Q4 2025 | 6.4% | +0.3 points |
| Q3 2025 | 3.9% | -5 points |
| Q2 2025 | 10% | +5.7 points |
| Q1 2025 | 10% | +6.7 points |
| Q4 2024 | 6.1% | +5.3 points |
| Q3 2024 | 8.9% | +4 points |
MDA has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
MDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$102.4M | -2464% |
| Q1 2026 | -$4.5M | -102% |
| Q4 2025 | $11.7M | -95% |
| Q3 2025 | -$12.2M | -107% |
| Q2 2025 | $4.3M | -95% |
| Q1 2025 | $205.3M | +$207M |
| Q4 2024 | $230.2M | +$297M |
| Q3 2024 | $164.1M | +$213.5M |
MDA has the edge over ASTS on cash flow, with more consistent year-over-year improvement.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over MDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
MDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +9.8M shares |
| 1 year | +11% | +14.5M shares |
| 3 years | +19% | +22.3M shares |
| 5 years | +20% | +23.8M shares |
MDA has 143M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
MDA hasn't bought back shares in the past year.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
| Q3 2024 | 1.7x | Healthy |
MDA has more cash than debt.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
MDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 22.8 | Neutral |
MDA's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
MDA PE vs Technology Sector
| Metric | MDA | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 28x | 84% above |
| PE % | 58 | 18 | 40 pts above |
MDA is trading at 51x earnings, a 84% premium to the Technology sector's median of 28x, though its earnings don't support one.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
MDA has stronger trend alignment. ASTS is above 1 of 5 weekly averages versus MDA above 1 of 2.
MDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.4% above |
| 20 week MA | $30.7 | 4.9% below |
MDA has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 4.9% below its 20-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
MDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $29.1 | $29.2 | +0.1% |
MDA has the edge over ASTS on returns for 2026, with the stronger performance.